GLP-1 drugs lower addiction overdose deaths in veterans
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GLP‑1 receptor agonists (semaglutide, liraglutide, dulaglutide) were associated with a lower incidence of new substance‑use disorders—including alcohol, nicotine, cannabis, cocaine, and opioids—among 524,817 veterans without prior SUD.
- GLP‑1 receptor agonists were linked to reduced rates of overdose, hospitalization, emergency department visits, and drug‑related death among 81,617 veterans who already had a diagnosed substance‑use disorder.
- The study examined electronic health records of 606,434 U.S. veterans with type‑2 diabetes over up to three years, comparing outcomes for GLP‑1 users versus those on SGLT2 inhibitors.
- The BMJ published the results on June 3 2026, highlighting the potential of GLP‑1 drugs to curb addiction across multiple substances.
Why it matters: Veterans with diabetes and clinicians gain a new tool to lower addiction risk and prevent overdose deaths, and health systems can reduce emergency‑care costs and substance‑use complications.
